Citizens Maintains Market Outperform on Iovance Biotherapeutics, Raises Price Target to $8
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Citizens analyst Reni J. Benjamin maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Market Outperform and raises the price target from $5 to $8.
Citizens analyst Reni J. Benjamin maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Market Outperform and raises the price target from $5 to $8.